
Opinion|Videos|October 25, 2023
Abiraterone’s Role in the Management of Prostate Cancer
Author(s)Benjamin H. Lowentritt, MD, FACS
Benjamin H. Lowentritt, MD, FACS, provides clinical insights on the use of different formulations of abiraterone as treatment for patients with prostate cancer.
Advertisement
Video Player is loading.
Episodes in this series

Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Christof Vulsteke, MD, PhD, breaks down findings, implications of KEYNOTE-905
2
The UroOnc Minute: Active Surveillance for Intermediate-risk Prostate Cancer, with Michael Leapman, MD, MHS
3
The Significance of KEYNOTE-905 in Muscle-Invasive Bladder Cancer
4
Petros Grivas, MD, on the significance of a perioperative regimen for cisplatin-ineligible MIBC
5






















